Takara Bio Inc. revised earnings guidance for the fiscal year ending March 31, 2022. For the period, the company expected net sales of JPY 59,300 million, operating profit of JPY 20,000 million, net income attributable to owners of the parent of JPY 14,100 million and net income per share of JPY 117.09 compared to previous guidance of net sales of JPY 54,200 million, operating profit of JPY 17,000 million, net income attributable to owners of the parent of JPY 11,900 million and net income per share of JPY 98.82.